Rom Leidner

TL;DR: The authors show that CD39 and CD103 mark a subset of tumor-infiltrating CD8 T cells that are tumor-reactive and exhibit characteristics of exhausted or tissue-resident memory T cells, which may lead to future adoptive T-cell cancer therapies.

TL;DR: An expert committee formed by the Society for Immunotherapy of Cancer formed an expert committee tasked with generating consensus recommendations for emerging immunotherapies, including appropriate patient selection, therapy sequence, response monitoring, adverse event management, and biomarker testing serve as a foundation to assist clinicians’ understanding of the role of immunotherAPies.

TL;DR: It is demonstrated that D USP6 expression tracks in tandem with ERK inhibition and that regulation of DUSP6 is mediated at the promoter level by ETS1, a well-known nuclear target of activated ERK.

TL;DR: It is found that, consistent with previous reports, high numbers of CD8+ T cells at the invasive margin correlated significantly with prolonged overall survival (OS), while the number of FoxP3+ or PD-L1+ cells did not.

TL;DR: These case reports suggest that UV-associated skin cancers, beyond melanoma, are sensitive to PD-1 blockade, and are recommended to be treated with REGN2810, a fully human anti-PD-1 monoclonal antibody in an ongoing phase 1 trial.